pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Datroway
drug · antibody drug conjugate
save

datopotamab deruxtecan

pre_registrationupdated 6mo ago
by Daiichi Sankyo Co Ltd🔗 ChEMBL
community read0 votes

Antibody drug conjugate drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.

indications

indications
NSCLC

targets

DNA topoisomerase 1Tumor-associated calcium signal transducer 2

all catalysts(0)

nothing on the calendar yet

Trials studying datopotamab deruxtecan

  • phase3Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)active not recruitingn=1,233
  • phase2Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastasesactive not recruitingn=20
  • phase2Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignanciesrecruitingn=695
  • phase3Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterationsactive not recruitingn=740
  • phase2Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)recruitingn=454
  • phase1First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)active not recruitingn=890
  • phase2A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)recruitingn=46
  • phase2TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXdrecruitingn=357

News(10)

  • FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
    The FDA has issued a complete response letter to Summit Therapeutics, derailing the immediate U.S. launch of a drug class that many industry heavyweights believe could eventually dethrone Merck & C…
    fiercebiotech · 6d ago
  • Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
    With companies including AstraZeneca, Pfizer and Revolution Medicines clamoring to get in on Summit Therapeutics’ Akeso-partnered PD-1xVEGF antibody, one analyst calls the asset “the next major bac…
    biospace · 17d ago
  • ESMO 2026: Merck’s Kelun-partnered ADC hits the ‘Goldilocks zone,’ VP says
    At the European Society for Medical Oncology meeting this weekend, Merck will showcase three late-stage trials of its Kelun-Biotech–partnered TROP2-directed antibody sac-TMT that VP of Chemistry Al…
    biospace · 28d ago
  • Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestone
    Plus news about Regeneron. Summit Therapeutics to test cancer drug with Datroway: The biotech agreed to partner with AstraZeneca and Daiichi Sankyo on a clinical trial collaboration, testing its Tr…
    endpoints · 1mo ago
  • AstraZeneca’s newly approved pill fails frontline breast cancer study
    Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year.
    biopharma_dive · 2mo ago
  • BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
    BioNTech has linked gotistobart to a median overall survival of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.
    fiercebiotech · 2mo ago
  • As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
    While both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be mo…
    biospace · 3mo ago
  • ‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
    If AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.
    biospace · 3mo ago
  • Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
    Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, cost numerous jobs, all while damaging the broader biopharma ecosystem and hurting patien…
    fiercebiotech · 3mo ago
  • Daiichi’s pipeline falls behind rivals as cash flow nears peak: analysts
    With Enhertu and Datroway hitting their peak revenue and rivals flowing into the antibody-drug conjugate space, Jefferies cuts expectations for Daiichi Sankyo.
    biospace · 3mo ago
view all news mentions →
brand
Datroway
generic
datopotamab deruxtecan
MOA
DNA topoisomerase I inhibitor; Tumor-associated calcium signal transducer 2 binding agent
indication
Triple-Negative Breast Cancer (TNBC)
phase
pre_registration
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?